X

Trial Profile

A Managed Access Program for lenzilumab for hospitalized patients with COVID-19

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenzilumab (Primary)
Indications COVID 2019 infections
Focus Expanded access; Therapeutic Use
Acronyms LenzMAP

Most Recent Events

18 Oct 2021 New trial record
08 Oct 2021 According to a Humanigen media release, the company has has entered into an arrangement with Clinigen Group plc "Clinigen" a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab "LenzMAP". Under the terms of the agreement, Clinigen will manage key elements of the program including regulatory oversight, logistics and access management.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com